Exchange Traded Concepts LLC Purchases 1,369 Shares of Regeneron Pharmaceuticals, Inc. $REGN

Exchange Traded Concepts LLC increased its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 34.7% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 5,309 shares of the biopharmaceutical company’s stock after purchasing an additional 1,369 shares during the period. Exchange Traded Concepts LLC’s holdings in Regeneron Pharmaceuticals were worth $2,985,000 at the end of the most recent reporting period.

Several other hedge funds also recently bought and sold shares of the company. Activest Wealth Management lifted its position in shares of Regeneron Pharmaceuticals by 110.5% in the first quarter. Activest Wealth Management now owns 40 shares of the biopharmaceutical company’s stock valued at $25,000 after acquiring an additional 21 shares in the last quarter. Saudi Central Bank bought a new stake in Regeneron Pharmaceuticals during the 1st quarter valued at approximately $27,000. Migdal Insurance & Financial Holdings Ltd. purchased a new position in Regeneron Pharmaceuticals in the 2nd quarter worth approximately $31,000. Traub Capital Management LLC bought a new position in Regeneron Pharmaceuticals in the 2nd quarter worth approximately $38,000. Finally, Berbice Capital Management LLC grew its holdings in Regeneron Pharmaceuticals by 300.0% during the 2nd quarter. Berbice Capital Management LLC now owns 80 shares of the biopharmaceutical company’s stock valued at $42,000 after buying an additional 60 shares in the last quarter. Institutional investors own 83.31% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts have recently commented on REGN shares. Raymond James Financial raised shares of Regeneron Pharmaceuticals to a “moderate buy” rating in a report on Tuesday, September 2nd. Canaccord Genuity Group lifted their price target on shares of Regeneron Pharmaceuticals from $850.00 to $1,057.00 and gave the company a “buy” rating in a report on Thursday, December 4th. Truist Financial initiated coverage on shares of Regeneron Pharmaceuticals in a report on Monday, November 24th. They set a “buy” rating and a $798.00 price objective for the company. Wall Street Zen lowered Regeneron Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Saturday, December 20th. Finally, Bank of America increased their price target on Regeneron Pharmaceuticals from $543.00 to $627.00 and gave the company an “underperform” rating in a research note on Wednesday, October 29th. Three equities research analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating, eight have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $779.45.

Regeneron Pharmaceuticals Price Performance

NASDAQ:REGN opened at $779.70 on Friday. The firm has a market capitalization of $81.95 billion, a price-to-earnings ratio of 18.67, a PEG ratio of 2.25 and a beta of 0.37. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.06 and a quick ratio of 3.33. The business has a 50 day simple moving average of $699.36 and a 200-day simple moving average of $607.79. Regeneron Pharmaceuticals, Inc. has a 1 year low of $476.49 and a 1 year high of $792.77.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its earnings results on Tuesday, October 28th. The biopharmaceutical company reported $11.83 earnings per share for the quarter, beating the consensus estimate of $9.73 by $2.10. The firm had revenue of $3.75 billion for the quarter, compared to the consensus estimate of $3.57 billion. Regeneron Pharmaceuticals had a return on equity of 13.76% and a net margin of 32.13%.The company’s revenue for the quarter was up .9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $12.46 EPS. Equities analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Friday, December 5th. Stockholders of record on Thursday, November 20th were issued a $0.88 dividend. This represents a $3.52 annualized dividend and a dividend yield of 0.5%. The ex-dividend date was Thursday, November 20th. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is 8.43%.

Insider Transactions at Regeneron Pharmaceuticals

In other Regeneron Pharmaceuticals news, VP Jason Pitofsky sold 431 shares of the firm’s stock in a transaction dated Friday, November 7th. The shares were sold at an average price of $651.43, for a total value of $280,766.33. Following the completion of the sale, the vice president owned 4,233 shares of the company’s stock, valued at $2,757,503.19. This trade represents a 9.24% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Christine A. Poon sold 6,500 shares of the company’s stock in a transaction that occurred on Wednesday, October 29th. The shares were sold at an average price of $654.27, for a total value of $4,252,755.00. Following the transaction, the director directly owned 2,352 shares in the company, valued at approximately $1,538,843.04. This represents a 73.43% decrease in their position. The SEC filing for this sale provides additional information. 7.02% of the stock is currently owned by insiders.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.